376 results on '"Geng, Cuizhi"'
Search Results
102. Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women
103. Urban Rural Disparity in Westernization Related Cancers and the Increasing Incidence in Parallel with Socioeconomic Development and Urbanization from 2000-2015 among a Rural Chinese Population: An Observational Study
104. Analysis of risk factors for implantable venous access port catheter fracture with internal jugular vein
105. Artificial Intelligence Treatment Decision Support For Complex Breast Cancer Among Oncologists With Varying Expertise
106. Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation
107. Is it beneficial for patients with pT1‐2N1M0 breast cancer to receive postmastectomy radiotherapy? An analysis based on RecurIndex assay.
108. Glycogen-rich clear cell carcinoma of the breast: Two-Case report
109. Unsuccessful removal of a totally implantable venous access port caused by thrombosis in the left brachiocephalic vein
110. Clinical analysis of 150 patients with periampullary carcinoma
111. CircRNA ZNF609 promotes the growth and metastasis of thyroid cancer in vivoand in vitroby downregulating miR-514a-5p
112. Identification of core genes and potential molecular mechanisms in breast cancer using bioinformatics analysis
113. LncRNA PAPAS may promote triple-negative breast cancer by downregulating miR-34a
114. Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer.
115. The Effect of the Leptin and Leptin Receptor Expression on the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
116. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer
117. Association of PTPN1 polymorphisms with breast cancer risk: A case‐control study in Chinese females
118. Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
119. Circular RNA ciRS-7 Maintains Metastatic Phenotypes as a ceRNA of miR-1299 to Target MMPs
120. Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.
121. Comparison of surgical complication between immediate implant and autologous breast reconstruction after mastectomy: A multicenter study of 426 cases
122. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors
123. miR‑92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2
124. Concordance, decision impact and guidelines adherence using artificial intelligence in high-risk breast cancer.
125. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention
126. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China
127. Surgical management associates independently with improved survival among de novo stage IV breast cancer patients without liver or brain metastasis.
128. Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.
129. Fluorescence Imaging Combined with Ultrasound in SLN Biopsy of Breast Cancer
130. Primary squamous cell carcinoma of the breast—3 cases report
131. Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes
132. Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer.
133. Interpreting Advanced Breast Cancer Consensus Guidelines for Use in China
134. Incidence rate of female breast cancer in urban Shijiazhuang in 2012 and modifiable risk factors
135. Single nucleotide polymorphisms in the mitochondrial displacement loop and age-at-onset of familial breast cancer
136. Totally implantable venous access port systems and associated complications: A single-institution retrospective analysis of 2,996 breast cancer patients
137. Mucoepidermoid carcinoma of the breast: Four case reports and review of the literature.
138. Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021.
139. Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study.
140. Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.
141. Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.
142. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
143. Education of health professionals in China
144. Hyponatremia Induced by Low-Dose Cyclophosphamide in two Patients with Breast Cancer
145. LIM-domain-only proteins: multifunctional nuclear transcription coregulators that interacts with diverse proteins
146. Estrogen receptor β inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2
147. Overexpression of 14-3-3σ counteracts tumorigenicity by positively regulating p73 in vivo
148. p73-dependent induction of 14-3-3σ increases the chemo-sensitivity of drug-resistant human breast cancers
149. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
150. Author Correction: Epigenetic study of early breast cancer (EBC) based on DNA methylation and gene integration analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.